Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammary Analogue Secretory Carcinoma | 1 | 2023 | 8 | 0.840 |
Why?
|
| Oropharyngeal Neoplasms | 5 | 2022 | 268 | 0.830 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2023 | 60 | 0.800 |
Why?
|
| Carcinoma | 1 | 2023 | 301 | 0.680 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 115 | 0.510 |
Why?
|
| Hemangiosarcoma | 2 | 2014 | 46 | 0.470 |
Why?
|
| Splenic Neoplasms | 1 | 2014 | 12 | 0.430 |
Why?
|
| Leukocytosis | 1 | 2014 | 48 | 0.420 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 233 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 174 | 0.320 |
Why?
|
| Anemia | 1 | 2014 | 350 | 0.320 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 189 | 0.310 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2011 | 149 | 0.310 |
Why?
|
| Scleroderma, Systemic | 3 | 2016 | 129 | 0.290 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2019 | 763 | 0.290 |
Why?
|
| Lung | 2 | 2011 | 1556 | 0.250 |
Why?
|
| Fatal Outcome | 3 | 2014 | 378 | 0.230 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2005 | 26 | 0.230 |
Why?
|
| Influenza, Human | 1 | 2011 | 700 | 0.220 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 385 | 0.220 |
Why?
|
| Gingiva | 1 | 2023 | 11 | 0.210 |
Why?
|
| Gene Fusion | 1 | 2023 | 60 | 0.200 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 443 | 0.190 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 775 | 0.180 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 234 | 0.180 |
Why?
|
| Translocation, Genetic | 1 | 2023 | 359 | 0.180 |
Why?
|
| Thrombosis | 1 | 2005 | 529 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 2 | 2022 | 615 | 0.160 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 956 | 0.150 |
Why?
|
| Fibroblasts | 3 | 2016 | 879 | 0.150 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1366 | 0.140 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 146 | 0.130 |
Why?
|
| Semaphorins | 1 | 2016 | 33 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 1686 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1442 | 0.120 |
Why?
|
| Demography | 1 | 2016 | 242 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 1450 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 305 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 238 | 0.110 |
Why?
|
| HLA-DRB1 Chains | 1 | 2014 | 45 | 0.110 |
Why?
|
| Skin | 2 | 2010 | 540 | 0.110 |
Why?
|
| Protein Transport | 1 | 2016 | 371 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 125 | 0.110 |
Why?
|
| Middle Aged | 8 | 2019 | 28847 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2166 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 817 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 49 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 578 | 0.100 |
Why?
|
| Prognosis | 3 | 2022 | 5006 | 0.100 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 313 | 0.100 |
Why?
|
| Humans | 17 | 2023 | 132278 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 806 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1303 | 0.090 |
Why?
|
| Genotype | 2 | 2016 | 2704 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 2686 | 0.090 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2011 | 23 | 0.090 |
Why?
|
| Biocatalysis | 1 | 2011 | 35 | 0.090 |
Why?
|
| Male | 12 | 2019 | 64993 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 694 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 729 | 0.080 |
Why?
|
| Osteonectin | 1 | 2010 | 5 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1295 | 0.080 |
Why?
|
| Pulmonary Fibrosis | 1 | 2010 | 112 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2011 | 621 | 0.070 |
Why?
|
| Adult | 7 | 2018 | 31585 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 2067 | 0.070 |
Why?
|
| Aged | 6 | 2019 | 21347 | 0.070 |
Why?
|
| Veterans | 2 | 2015 | 1755 | 0.060 |
Why?
|
| Fenretinide | 1 | 2005 | 9 | 0.060 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2005 | 53 | 0.060 |
Why?
|
| HIV Infections | 1 | 2018 | 2022 | 0.060 |
Why?
|
| Catastrophic Illness | 1 | 2005 | 3 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 127 | 0.060 |
Why?
|
| Female | 10 | 2019 | 70773 | 0.060 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2005 | 20 | 0.060 |
Why?
|
| Vascular Neoplasms | 1 | 2005 | 33 | 0.060 |
Why?
|
| Skin Ulcer | 1 | 2005 | 32 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 117 | 0.050 |
Why?
|
| Risk Factors | 2 | 2016 | 10894 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2005 | 358 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2005 | 145 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3355 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2005 | 461 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2022 | 183 | 0.040 |
Why?
|
| Smoking | 2 | 2015 | 941 | 0.040 |
Why?
|
| Transfection | 2 | 2011 | 1020 | 0.040 |
Why?
|
| Gene Expression | 2 | 2016 | 1569 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2022 | 361 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2019 | 92 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2005 | 1597 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 79 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 127 | 0.030 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2016 | 18 | 0.030 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2016 | 12 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2016 | 23 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 142 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 2016 | 31 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2016 | 108 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 1828 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 1880 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 2015 | 10 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 312 | 0.030 |
Why?
|
| Carcinogens | 1 | 2015 | 129 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1723 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 3700 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 97 | 0.030 |
Why?
|
| China | 1 | 2014 | 290 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 665 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2015 | 346 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 894 | 0.020 |
Why?
|
| Alcoholism | 1 | 2015 | 250 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1127 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 359 | 0.020 |
Why?
|
| Diet | 1 | 2019 | 1173 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1569 | 0.020 |
Why?
|
| Sumoylation | 1 | 2011 | 41 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 3358 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 196 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2010 | 21 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2010 | 123 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2010 | 124 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2010 | 106 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5399 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2515 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2010 | 241 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1086 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 543 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 1583 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1294 | 0.020 |
Why?
|
| Fibrosis | 1 | 2010 | 428 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2849 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2015 | 17344 | 0.020 |
Why?
|
| Mice | 2 | 2016 | 18622 | 0.020 |
Why?
|
| Texas | 1 | 2015 | 3629 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 90 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 5145 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 3700 | 0.010 |
Why?
|
| Clone Cells | 1 | 2005 | 179 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 2460 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 3071 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2002 | 36 | 0.010 |
Why?
|
| Animals | 2 | 2016 | 35136 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 456 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 13002 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 748 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4773 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 4681 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 1990 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 2072 | 0.010 |
Why?
|